COMMUNIQUÉS West-GlobeNewswire

Shineco Announces Acquisition of Medical Device Company
25/03/2025
The Acquisition is Expected to Create Immediate Synergies with the Company’s Existing Medical Device Business BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a [...]
Emerald Isle Health & Recovery Announces New Chief Executive Officer
25/03/2025
SUN CITY, Ariz., March 25, 2025 (GLOBE NEWSWIRE) -- Emerald Isle Health & Recovery proudly announces the appointment of Danielle Siragusa, LCSW, as its new Chief Executive Officer. A dynamic and results-driven [...]
Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference
25/03/2025
AGOURA HILLS, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), ”), a leader in RNA-based therapeutics, announced today the successful [...]
Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada
25/03/2025
Diabetinol ® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace DALLAS, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: [...]
Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity
25/03/2025
Helicore’s first-in-human study is designed to evaluate the safety and tolerability of HCR-188 in a single and multiple ascending dose study Top-line safety data anticipated in the second half of 2025 SOUTH SAN [...]
Marius Pharmaceuticals Strengthens IP Portfolio with New KYZATREX® (testosterone undecanoate) CIII Capsules Formulation Patent
25/03/2025
RALEIGH, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals , a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, announced today that the United States Patent [...]
Intelligent Bio Solutions’ FDA Clearance Process Remains on Track for 2025 U.S. Launch
25/03/2025
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Digital Utilities Ventures Acquires Lifestyle Dock Company, and Expands Market Reach for Easy NanoVoid™ Technology
25/03/2025
Acquisition Provides Strategic East Coast Manufacturing Facility and Strengthens International Distribution Capabilities Key Highlights: Strategic Acquisition for Market Expansion : Digital Utilities Ventures (OTC: DUTV [...]
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
25/03/2025
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3, [...]
Roche Annual General Meeting 2025
25/03/2025
Shareholders approved all proposals of the Board of Directors Severin Schwan was re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed 38th consecutive dividend [...]
Assemblée générale 2025 de Roche
25/03/2025
Adoption de toutes les propositions du Conseil d’administration Réélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les autres membres du Conseil d’administration qui se sont [...]
NervGen Pharma to Host Virtual Investor Event
25/03/2025
Key opinion leaders and company management will discuss the current spinal cord injury treatment landscape and NervGen's Phase 1b/2a clinical trial evaluating NVG-291 in individuals with spinal cord injury VANCOUVER, [...]
Syncromune Appoints Zhihong Li, Ph.D., as Chief Regulatory Affairs Officer to Lead Global Regulatory Strategy for Novel Oncology Immunotherapies
25/03/2025
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, March 25, 2025 (GLOBE NEWSWIRE) -- Syncromune ® Inc., a clinical-stage biopharmaceutical company developing SYNC-T, an in situ personalized immunotherapy platform [...]
Epilepsy Foundation of America Harnesses the “Power in Purple” for Special Awareness Day
25/03/2025
Purple Day® encourages education, support, and advocacy for the epilepsy community BOWIE, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Join the Epilepsy Foundation of America for Purple Day® on March 26, 2025 to uplift the “ [...]
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
25/03/2025
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected [...]
TOMI Environmental Solutions, Inc. Partners with Pharma Biotech System Components to Enhance Disinfection Solutions
25/03/2025
FREDERICK, Md., March 25, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a leader in disinfection and decontamination solutions, today announced an OEM partnership with Pharma [...]
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
25/03/2025
– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all [...]
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
25/03/2025
Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s unwavering [...]
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
25/03/2025
- U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval - WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE [...]

Pages